Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 2, 2006, Pages 135-139

  Holmberg, Leona A ^a,b   Maloney, David ^a,b   Bensinger, William ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Follicular lymphoma; Interferon; Maintenance therapy; Neutropenia; Peripheral blood stem cells; Radiation therapy

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; FATALITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; INJECTION SITE INDURATION; INJECTION SITE PAIN; LARGE CELL LYMPHOMA; LUNG DISEASE; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; STEM CELL TRANSPLANTATION; SUBDURAL HEMATOMA; SURVIVAL RATE; T CELL LYMPHOMA; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 33750180098     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.051     Document Type: Article

References (23)

1. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10:116-127.
2. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7:294-301.
3. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16:618-624.
4. Welte K, Ciobanu N, Moore MA, et al. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 1984; 64:380-385.
5. Bosly A, Brice P, Humblet Y, et al. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. Nouv Rev Fr Hematol 1990; 32:13-16.
6. Hernandez MD, del Canizo MC, Gonzalez M, et al. Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation. Med Clin (Barc) 1998; 110:768-773.
7. Cayeux S, Meuer S, Pezzutto A, et al. T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogenous IL-2. Blood 1989; 74:2270-2277.
8. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88:637a (Abstract #2535).
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
10. Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:281-289.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
12. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004; 10:6101-6110.
13. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of Interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlates with clinical response. Clin Cancer Res 2004; 10:2253-2264.
14. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haemat 2002; 117:828-834.
15. Fefer A, Robinson N, Benyunes MC, et al. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am 1997; 3(suppl 1):S48-S53.
16. Bosly A, Guillaume T, Brice P, et al. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 1992; 20:962-968.
17. Lauria F, Raspadori D, Ventura MA, et al. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18:79-85.
18. Vey N, Blaise D, Tiberghien P, et al. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leuk Lymphoma 1996; 21:107-114.
19. Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29:56-69.
20. Schmitz N. Rituximab in autologous stem cell transplantation for follicular lymphoma. Anticancer Drugs 2001; 12:S21-S24.
21. Tsai D, Moore H, Hardy C, et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24:521-526.
22. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103:777-783.
23. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.